These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 3121273)
1. Influence of long-term aldose reductase inhibitor therapy on autonomic dysfunction of urinary bladder, stomach and cardiovascular systems in diabetic patients. Green A; Jaspan J; Kavin H; Chung S; Schoenberg H Diabetes Res Clin Pract; 1987 Nov; 4(1):67-75. PubMed ID: 3121273 [TBL] [Abstract][Full Text] [Related]
2. Effects of sorbinil therapy in diabetic patients with painful peripheral neuropathy and autonomic neuropathy. Jaspan JB; Herold K; Bartkus C Am J Med; 1985 Nov; 79(5A):24-37. PubMed ID: 3000176 [TBL] [Abstract][Full Text] [Related]
3. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Jaspan JB; Towle VL; Maselli R; Herold K Metabolism; 1986 Apr; 35(4 Suppl 1):83-92. PubMed ID: 3083212 [TBL] [Abstract][Full Text] [Related]
4. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy. Failure to improve abnormal nerve function. Martyn CN; Reid W; Young RJ; Ewing DJ; Clarke BF Diabetes; 1987 Sep; 36(9):987-90. PubMed ID: 3111914 [TBL] [Abstract][Full Text] [Related]
5. Treatment of severely painful diabetic neuropathy with an aldose reductase inhibitor: relief of pain and improved somatic and autonomic nerve function. Jaspan J; Maselli R; Herold K; Bartkus C Lancet; 1983 Oct; 2(8353):758-62. PubMed ID: 6137601 [TBL] [Abstract][Full Text] [Related]
7. Clinical and neurophysiological studies with the aldose reductase inhibitor, sorbinil, in symptomatic diabetic neuropathy. Lewin IG; O'Brien IA; Morgan MH; Corrall RJ Diabetologia; 1984 Jun; 26(6):445-8. PubMed ID: 6432615 [TBL] [Abstract][Full Text] [Related]
8. The effect of an aldose reductase inhibitor on cardiovascular performance in patients with diabetes mellitus. Roy TM; Broadstone VL; Peterson HR; Snider HL; Cyrus J; Fell R; Rothchild AH; Samols E; Pfeifer MA Diabetes Res Clin Pract; 1990; 10(1):91-7. PubMed ID: 2123430 [TBL] [Abstract][Full Text] [Related]
9. Autonomic and peripheral nerve function in early diabetic neuropathy. Possible influence of a novel aldose reductase inhibitor on autonomic function. Sundkvist G; Lilja B; Rosén I; Agardh CD Acta Med Scand; 1987; 221(5):445-53. PubMed ID: 3111179 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological inhibition of aldose reductase in human diabetic neuropathy. Jaspan J Drugs; 1986; 32 Suppl 2():23-9. PubMed ID: 2431859 [TBL] [Abstract][Full Text] [Related]
16. Aldose reductase inhibitors and late complications of diabetes. Benfield P Drugs; 1986; 32 Suppl 2():43-55. PubMed ID: 3098544 [TBL] [Abstract][Full Text] [Related]
17. The effect of an aldose reductase inhibitor (Sorbinil) on diabetic neuropathy and neural function of the retina: a double-blind study. Christensen JE; Varnek L; Gregersen G Acta Neurol Scand; 1985 Feb; 71(2):164-7. PubMed ID: 3920861 [TBL] [Abstract][Full Text] [Related]
18. Recent advances in the therapy of diabetic peripheral neuropathy by means of an aldose reductase inhibitor. Greene DA; Lattimer SA Am J Med; 1985 Nov; 79(5A):13-7. PubMed ID: 3000175 [TBL] [Abstract][Full Text] [Related]